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Cocrystals are modular multicomponent solids with exceptional utility in synthetic chemistry and materials
science. A variety of methods exist for the preparation of cocrystals, yet, some promising cocrystal phases
have proven to be intractable synthetic targets. We describe a strategy for the synthesis of the
pharmaceutically relevant (caﬀeine)$(benzoic acid) cocrystal (1), which persistently failed to form using a
broad range of established techniques. State-of-the-art crystal structure prediction methods were
employed to assess the possible existence of a thermodynamically stable form of 1, hence to identify
appropriate heteronuclear seeds for cocrystallization. Once introduced, the designed heteronuclear
seeds facilitated the formation of 1 and, signiﬁcantly they (or seeds of the product cocrystal) continued
to act as long-lasting laboratory “contaminants”, which encouraged cocrystal formation even when
present at such low levels as to evade detection. The seeding technique described thus enables the
synthesis of cocrystals regarded as unobtainable under desired conditions, and potentially signiﬁes a
new direction in the ﬁeld of materials research.Introduction
In many areas of applied solid-state research, including the
pharmaceutical eld, it is crucial that a compound in develop-
ment be prepared and characterized in the largest possible
number of solid forms (e.g. polymorphs, salts, cocrystals).1 The
identication of a wide range of solid forms improves the
likelihood of identifying solids with optimal physicochemical
properties,2,3 and simultaneously maximizes patent protection
opportunities.4,5 For those industries focused on crystalline
solids, this approach may alleviate the risk of encountering new
solid forms of a compound aer substantial investments in
product development and marketing.6 Consequently, extensivebridge, Cambridge CB2 1EW, UK. E-mail:
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Chemistry 2013screening for alternative solid forms is seen as a vital step in any
solid materials development program.
The risks inherent in the development and marketing of
organic solids in the pharmaceutical arena are well illustrated
by the widely-known cases of the HIV protease inhibitor Rito-
navir7 (Norvir), and the dopamine agonist Rotigotine8 (Neupro).
A second polymorph of Ritonavir was found two years aer
Norvir was placed on the market. It transpired that this unex-
pected second polymorph was thermodynamically more stable
than the marketed one,9 rendering the initial polymorph
unobtainable for a substantial period and thus necessitating its
temporary removal from the market.7 Rotigotine, which was
used for the treatment of Parkinson's disease, was administered
through a skin patch to minimize the unpleasant side eﬀects of
the drug.8 Soon aerNeuprowas released on themarket in 2006,
a previously unknown and thermodynamically more stable
polymorph started to emerge in the Neupro skin patches.10 The
unexpected appearance of this new polymorph drastically
reduced the eﬃcacy of the patches, and led to a temporary
withdrawal of the drug from the market.
The appearance of a previously unknown polymorph,
accompanied by the complete disappearance of the initially
observed form, has been reported before.11 Such disappearing
polymorphs may be recovered by the tedious determination of
the precise crystallisation conditions that led to their formation
in the rst place.12 In addition, computational crystal structureChem. Sci., 2013, 4, 4417–4425 | 4417
Fig. 1 While cocrystallization attempts of caf and BA regularly fail, cocrystal 1 is
readily accessible when (caf)$(FBA) cocrystals are used as heteronuclear seeds.
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View Article Onlinepredictions,13 as well as knowledge-based hydrogen-bond
prediction,14 can be utilized to assess the likelihood that addi-
tional polymorphsmay exist, and to evaluate relative polymorph
stability. Despite these possible solutions, the prospect of
encountering new and unanticipated solid forms that might
lead to the withdrawal of a product from the market – even for a
short period of time – still remains daunting.5,7
While the inability to constrain the formation of new poly-
morphs can have disastrous consequences for a marketed drug,
unsuccessful attempts to prepare a multi-component solid (e.g.
salt or cocrystal15) can raise the question of whether the solid is
actually obtainable in the rst place. In particular, since the
crystallization of such a solid competes with the crystallization
of the pure components or their solvates/hydrates, it can be
quite diﬃcult to estimate whether the formation of the crys-
tallized solid is even thermodynamically favorable. Unobtain-
able (or at least apparently “hidden”16) solid forms with
potentially desirable properties are problematic for multiple
reasons: for example, an initial failure to obtain a cocrystal
might give competing interests a market entry if the synthesis of
this “hidden” solid was subsequently accomplished.6
Crystal engineering and cocrystallization (i.e. the formation
of multi-component crystalline solids) have recently emerged as
important tools for the development of functional organic
materials17–29 and for maximum patent protection.4,5 A bur-
geoning area in this eld is the development of eﬃcient and
rapid cocrystal screening techniques. Techniques are sought to
assure cocrystal formation, assuming that a cocrystal phase
exists under desired conditions (e.g. standard ambient condi-
tions). Numerous screening methods (mechanochemical,30,31
thermal,32,33 and solution-based34) and crystallization tech-
niques (such as heteronuclear seeding35,36) have been applied to
cocrystal screening. These methods are generally used in an
integrated manner to prepare the maximum number of crystal
forms of a given molecule. The eld, however, still lacks a
general methodology that would allow and ensure the crystal-
lization of all designed solid forms predicted to be attainable.
Here, we present an approach that uses pre-designed heter-
onuclear seeds to facilitate the synthesis of the elusive cocrystal
1 based on caﬀeine (caf) and benzoic acid (BA) in a 1 : 1 ratio.
Despite the components' apparent propensity for self-
assembly,37,38 1 has failed to form in the past,39,40 nor was it
prepared by our persistent cocrystallization attempts in four
laboratories that involved the use of various established coc-
rystallization methods. Following a computational study using
crystal structure prediction methods, which showed that
formation of 1 is thermodynamically favorable, the predicted
cocrystal was ultimately obtained by heteronuclear seeding,
using structurally related cocrystals, consisting of caf and u-
orobenzoic acids (FBA), as seeds (Fig. 1). The adoption of such a
seeding strategy41 was motivated by the successful use of crystal-
structure prediction in the synthesis of a previously unobserved
polymorph of a pharmaceutical compound.42
It is particularly noteworthy that, aer our initial success
with seeding, 1 then remained attainable for several months in
all four laboratories where these experiments were conducted,
without the need for the deliberate introduction of the seeds.4418 | Chem. Sci., 2013, 4, 4417–4425The ndings presented here have signicant implications
for solid-state and materials science, as well as for pharma-
ceutical and biomedical researchers. Specically, this work
suggests that elusive cocrystals, sometimes rashly regarded as
nearly unobtainable (or even nonexistent under desired condi-
tions) because of their presumed unfavorable lattice energies,
might actually be readily available using designed hetero-
nuclear seeds. Our ndings also highlight the failings in our
current understanding of the nucleation process of cocrystals,
and the consequences of such decient knowledge for progress
in materials development.
The work presented here describes the eﬀorts of four labo-
ratories to prepare 1, a solid of pharmaceutical interest whose
synthesis has been previously unsuccessfully attempted by
others during the last sixty years.39,40 Our interest in 1 is three-
fold. First, it arises from the sunscreen eﬀect of physical
mixtures of caf and sodium benzoate (SB).43 Second, equimolar
solutions of caf and SBwere found to facilitate electroconvulsive
therapy,44 and used to treat postdural puncture headaches and
migraine attacks.45 In such solutions, SB (or alternatively, citric
acid) is added to enhance the solubility of caf and to maintain
the solution as sterile. Notably, the presence of undissociated
BA in the caf solution might be more desirable (as BA is a more
eﬀective antimicrobial agent for preservation purposes than the
dissociated SB46), further driving eﬀorts to prepare 1. Third, our
interest in 1 was also triggered by our previous ndings in
related studies that caf invariably cocrystallizes with a broad
range of carboxylic acids, and that cocrystal 1 was the only co-
crystal that remained elusive.37,38,47,48
Experimental section
Crystal structure prediction
The crystal structure prediction study involved four steps. First,
trial crystal structures were generated in 15 space groups (i.e. P1,
P1, P21, P21/c, P21212, P212121, Pna21, Pca21, Pbca, Pbcn, C2/c, Cc,
C2, Pc and P2/c) using the CrystalPredictor program,49 which
generates structures using a low-discrepancy sequence toThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinesample the degrees of freedom that dene the crystal structure
(unit cell parameters, molecular positions and orientations). All
trial structures were built from one caf and one BA molecule in
the asymmetric unit. Molecular structures were kept rigid at
this stage, at geometries obtained from isolated molecule
optimization at the B3LYP/6-311G** level of theory, using
Gaussian03.50 Intermolecular interactions were modeled using
an exp-6 repulsion–dispersion model and an atomic partial
charge electrostatic model. The FIT parameter51 set was used for
repulsion–dispersion parameters and atomic partial charges
were calculated by tting to the B3LYP/6-311G** molecular
electrostatic potential, using the CHelpG scheme of tting
points. A total of 1.6 million trial structures were generated and
energy minimized during the initial search. In the second step,
rigid-molecule lattice energy minimizations were performed on
approximately 13 000 of the lowest energy structures with an
improved intermolecular model potential, using the same exp-6
repulsion–dispersion parameters as in the structure generation
step, now coupled with an atomic multipole model for electro-
static interactions, deriving multipoles up to hexadecapole on
each atom from a distributed multipole analysis (DMA)52 of the
B3LYP/6-311G** charge densities. These crystal structure
calculations were performed using DMACRYS.51 All intermolec-
ular interactions were summed to a 30 A˚ cutoﬀ, apart from
charge–charge, charge–dipole and dipole–dipole interactions,
for which Ewald summation was applied. The resulting struc-
tures were then clustered using the COMPACK algorithm to
remove duplicate structures, leaving 83 distinct crystal struc-
tures in a 10 kJ mol1 energy range from the global energy
minimum. In the third step, the 83 crystal structures were
re-optimized allowing the optimization of the caf methyl group
orientations, and of the dihedral angle between the phenyl ring
and the COOH plane in BA. These were performed using the
Crystal Optimizer53 code, which nds a minimum in the total
energy, calculated as the sum of intermolecular (FIT + DMA)
and intramolecular (B3LYP/6-311G**) energies, calling DMA-
CRYS51 for crystal structure calculations and Gaussian03 (ref. 50)
for molecular calculations. Finally, all structures obtained in
the third step were subjected to a nal rigid-molecule lattice
energy minimization using the same exp-6 repulsion–disper-
sion parameters, but with the DMA of each molecule calculated
from a charge density calculated with B3LYP/6-311G** within a
PCM54 representation of its solid state environment, which has
been shown to eﬀectively model the inuence of charge density
polarization on relative lattice energies.55 The PCM dielectric
was chosen as 3 ¼ 3.0, which is a typical value for the organic
solid state. The same lattice energy minimization steps
described in the third and fourth step were applied to ordered
models of caf and BA, as described in the main text.Cocrystal screens
The cocrystal screens were conducted in four laboratories under
various conditions and using several screening methods,
including neat grinding31 (NG), liquid-assisted grinding31 (LAG),
sonic slurry30 (SS) and solution-mediated phase trans-
formation34 (SMPT). The obtained solids were characterizedThis journal is ª The Royal Society of Chemistry 2013using powder X-ray diﬀraction and/or Raman spectroscopy.
Experimental details and summaries of results obtained from
each laboratory are provided in the ESI.†Cocrystal characterisation
The prepared cocrystals were characterised using powder X-ray
diﬀraction (PXRD), infrared spectroscopy, thermogravimetric
analysis, diﬀerential-scanning calorimetry, Raman spectros-
copy and, in some instances, 15N cross-polarisation magic-angle
spinning nuclear magnetic resonance spectroscopy (CP-MAS
NMR). Experimental details are given in the ESI.† The crystal
structures of the cocrystals were determined by ab initio crystal
structure solution by simulated annealing and Rietveld rene-
ment using powder X-ray data obtained from a laboratory
powder diﬀractometer. Experimental details and Rietveld plots
for all cocrystal structures are also available in the ESI.†Results and discussion
The preparation of cocrystal 1 was attempted in independent
trials by groups from the University of Cambridge, AbbVie Inc.,
the University of Zagreb and the University of Iowa, using
several highly reliable cocrystal screening methods viz., LAG,31
NG,31 SS30 and SMPT.34 These well-established screening
methods are trusted to facilitate cocrystal formation, provided
that such a cocrystal phase exists. In the SMPT and SS methods,
for example, the potential for cocrystal formation is maximized
once the activities of both components are kept at values higher
than their respective critical values, which is certainly accom-
plished in suspensions of physical mixtures of the cocrystal
components.34 The use of ultrasound in the SS method is also
known to facilitate cocrystal nucleation. The mechanochemical
methods (i.e. LAG and NG), on the other hand, enable the
formation of amorphous phases or eutectic mixtures through
the local heating induced by colliding mill balls.31
Despite the use of reliable screening methods, however, all
cocrystallization attempts failed in all four laboratories over
several years, and the negative outcome was largely attributed to
“crystal packing eﬀects”, i.e. the inability of the two components
to pack together in a suﬃciently stable crystal lattice.56
Considering that caf and BA form complexes in solution,57 as
well as the fact that caf is known to readily form cocrystals with
a broad variety of benzoic acid derivatives,58 it was intriguing
that such complex formation did not occur in the crystalline
solid state.
If it were able to form a solid-state complex, the complex
between caf and BA was felt more likely to be a cocrystal, rather
than a salt. This assumption was based primarily on the DpKa
value of the caf : BA pair (i.e., DpKa <3.5, see Table S2 in ESI†),
which clearly suggests the formation of a cocrystal.59 To assess
the probability that such a cocrystal is stable, global lattice
energy minimization calculations were performed to generate
the possible low energy structures of 1. A 1 : 1 stoichiometry was
assumed and crystal structures were generated using quasi-
random structure generation in 15 commonly observed space
groups, each with Z0 ¼ 1 (i.e. one caf and one BA per asymmetricChem. Sci., 2013, 4, 4417–4425 | 4419
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View Article Onlineunit). The most promising trial cocrystal structures generated
from an initial search were further optimized in several stages,
allowing for molecular exibility within each structure,
applying anisotropic models for interatomic interactions and
treating polarization of the molecular electron density by the
solid state environment. Energies and volumes of the resulting
predicted cocrystal structures are summarized in Fig. 2a.
To a rst approximation, the thermodynamic driving force
for cocrystallization can be assessed by comparing the calcu-
lated energies of the putative cocrystal structures with those of
the pure crystalline components; this approach has been
previously applied to predicting cocrystal formation, stoichi-
ometry and structure.60,61 In the present study, the known
crystal structure of BA, and an ordered version of the thermo-
dynamically stable form of caf at room temperature (Lehmann
and Stowasser's Z0 ¼ 5 ordered structure of b-caf62), were lattice
energy minimized using the same methods as used in theFig. 2 (a) Calculated lattice energies of the predicted cocrystal structures of 1,
compared to the sum of the pure component lattice energies (horizontal black
dashed line) and the sum of lattice energies and entropy resulting from orien-
tational disorder in pure caf (blue dashed line) and pure BA (the shaded areas
represent uncertainties in calculated energies due to the disorder); (b) crystal
packing in the P21/c lowest energy predicted cocrystal structure, viewed
approximately down the ab diagonal.
4420 | Chem. Sci., 2013, 4, 4417–4425cocrystal predictions. The calculated energy of this ordered
model of b-caf is an approximation of the lattice energy of the
orientationally disordered crystal structure, and we estimated
an uncertainty in the lattice energy of 1 kJ mol1 from the
spread in calculated lattice energies of the 512 unique possible
orientational congurations reported by Habgood.63Disorder in
the crystal structures of pure caf and BA provides an entropic
contribution to the stability of the pure forms, which, for b-caf,
were taken from Habgood63 as –TS z 1 kJ mol1 at room
temperature and were estimated as Sdisorderz R ln 2 for BA, due
to the two occupied congurations of the carboxylic acid group
in the hydrogen-bonded dimers in crystalline BA.
Even aer accounting for uncertainties in the calculated
lattice energies, and for the entropic contributions to
the stability of the pure forms, we found about 70 computer-
generated cocrystal structures that were predicted to be
energetically preferable to the pure single-component crystal
structures (Fig. 2a). The lowest energy predicted cocrystal
structure was shown to be more than 10 kJ mol1 more stable
than the pure components. We concluded from these compu-
tational studies that caf and BA are able to form a stable co-
crystal that, on thermodynamic grounds, should be realizable.
Furthermore, we were able to predict the likely primary inter-
action: all but one of the 70 lowest-energy predicted cocrystal
structures exhibit carboxylic-acid : imidazole O–H/N hydrogen
bonding (the lowest-energy predicted cocrystal structures are
available as ESI†). The hydrogen-bonded molecules are nearly
co-planar in the lowest-energy cocrystal structure, which is
sustained by C–H/O and p/p interactions (Fig. 2b).
Parallel to the computational study, the Cambridge group
commenced a structural study of related cocrystals, in order to
identify heteronuclear seeds that could potentially facilitate the
growth of 1. This study attempted the cocrystallization of caf
with structural isomers of mono-, di-, tri-, tetra- and penta-u-
orobenzoic acids (FBAs). Heteronuclear seeding has previously
been used to control polymorphism in metal–organic and
organic compounds, as well as in cocrystals.35,36,42,64 Our work,
however, applied this technique to facilitate the synthesis of
multicomponent solids that could not be obtained otherwise.
The working hypothesis for this study was that the formation
of 1 is presumably hindered by a high kinetic barrier65 and that
such a high barrier may be overcome by introducing a hetero-
nuclear seed that matches the target cocrystal structurally or
epitaxially.66,67 Specically, it was proposed that uorinated
benzoic acids (FBAs) would likely form cocrystals based on
molecular assemblies that are similar in size and shape to those
present in 1. Such an analogous assembly could be rationalized
by the relatively small size diﬀerence between hydrogen and
uorine atoms (van der Waals radii: 120 pm vs. 147 pm,68
respectively).69
Indeed, it was found that 17 (out of 19) isomers of FBAs form
cocrystals with caf.70 All the experimentally obtained cocrystal
structures were solved using powder diﬀraction data collected on
a laboratory diﬀractometer. The structural studies showed that
all (caf)$(FBA) cocrystals are based on caf : FBA complexes being
sustained by the same hydrogen-bonding motifs that are found
in the predicted structure of 1, namely imidazole–carboxylic-acidThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlineheterosynthons utilizing O–H/N hydrogen bonds (Fig. 3). Out of
these cocrystals, four (i.e. cocrystals involving 2-uorobenzoic
(2FBA), 2,3-diuorobenzoic (23diFBA), 2,5-diuorobenzoic
(25diFBA) and 2,6-diuorobenzoic (26diFBA)) were found to be
isomorphous with the lowest-energy predicted crystal structure
of 1 (i.e. the structures display the same space group and unit-cell
dimensions, as well as the same atom types and the positions,
except for an interchange of hydrogen and uorine within the
diﬀerent cocrystals).
Interestingly, once the (caf)$(FBA) cocrystals were synthe-
sized in the Cambridge laboratory, and before the actual seed-
ing experiments began there, the Cambridge group became
unable to replicate the previously negative results concerning
the cocrystallization of caf and BA. Specically, a new crystal
phase unexpectedly became achievable in every crystallization
attempt, as evidenced by powder diﬀraction studies and
thermal analyses (see Fig. S1, ESI†). This new crystal phase was
subsequently identied as the lowest energy predicted form of 1
(Fig. 4a–c) using crystal structure solution from powder X-ray
diﬀraction, natural abundance 15N CP-MAS NMR, and ther-
mogravimetric analysis.
The cocrystal was found to crystallize in the monoclinic P21/c
space group with one molecule of caf and BA in the asymmetric
unit interacting via the imidazole-carboxylic-acid heterosynthon
[d(O/N) ¼ 2.663(7) A˚] (Fig. 4a). Assemblies of caf : BA form
head-to-tail-oriented pairs that further stack in an oﬀset manner
(oﬀset: 7 A˚) held together by p/p interactions. The stacks
interact via weak C–H/p forces to form molecular sheets
exhibiting a herringbone motif (Fig. 4b). The sheets form a 3D
lattice being held together by C–H/p interactions.Fig. 3 X-ray crystal structures of (caf)$(FBA) cocrystals used as heteronuclear see
isomorphous with the lowest-energy predicted crystal structure of 1 (red label), unlike
a depiction of the caf: FBA (or caf : BA) assembly (top) and their crystal packing dia
red.
This journal is ª The Royal Society of Chemistry 2013Furthermore, 15N CP-MAS NMR was utilized to determine
whether the basic N(imidazole) atom of caf was protonated by
BA. Specically, it was shown that the solid-state 15N NMR
spectrum exhibits a signal at a high frequency (i.e. 194 ppm;
Fig. S16 in ESI†) that is consistent with the presence of an
unprotonated N(imidazole) atom in the studied solid.71
Considering that protonated N(imidazolate) atoms exhibit
peaks at lower-frequency chemical shis (i.e. 120–140 ppm),48 it
is was concluded that caf and BA crystallize as a cocrystal (rather
than a salt), as expected. Thermogravimetric analysis was
utilized to determine that the investigated caf : BA phase
consists solely of caf and BA (Fig. S18, ESI†).
One possible explanation for the unexpected formation of 1
was that the crystallization vessels or either batch of caf or BA
(or the environment in general) were contaminated with the
synthesized (caf)$(FBA) cocrystals, thus seeding the growth of
the target cocrystal. Surprisingly, 1 was found to form even
aer numerous thorough laboratory and equipment cleanups,
and the use of newly purchased glassware and batches of caf
and BA. More specically, the laboratory benches were thor-
oughly scrubbed using bleach and ethanol, whereas the milling
jars were cleaned using concentrated solutions of strong inor-
ganic acids and bases (i.e. HCl and NaOH, respectively). New
crystallization vials and milling balls were used in each exper-
iment, whereas all used solvents were heated and subsequently
ltered through syringe lters with polyvinylidene uoride
membranes displaying 0.2 mm pores. The very strong seeding
eﬀect of either (caf)$(FBA) crystals or crystals of 1, however,
persisted even one year aer the seeding experiments were
conducted, thus preventing comprehensive studies of theds for the crystallization of 1 (black labels). Structures shown in the ﬁrst row are
the structures shown in the second row. Each cocrystal system is represented with
grams (bottom). Colour scheme for the crystal packing diagrams: caf – blue, BA –
Chem. Sci., 2013, 4, 4417–4425 | 4421
Fig. 4 (a) X-ray crystal structure of a caf : BA assembly in 1; (b) X-ray crystal structure of a molecular sheet in 1 sustained by p/p and C–H/p interactions (inset
depicts two sheets stacked in an oﬀset manner); (c) overlay of the predicted (shown in red) and observed (blue) crystal structure of 1; (d) PXRD traces of solids obtained
in cocrystal screens with and without seeds at AbbVie Inc. [black: b-caf; grey: BA; red – from bottom to top: physical mixtures of caf and BA obtained in cocrystallization
attempt via LAG using nitromethane as liquid, LAG using ethanol as liquid, LAG using acetonitrile as liquid, NG, SMPTusing nitromethane as solvent, SMPTusing ethanol
as solvent, SMPT using acetonitrile as solvent; green – from bottom to top: 1 obtained via LAG using nitromethane as liquid and (caf)$(2FBA) as seed, LAG using
nitromethane as liquid and (caf)$(23diFBA) as seed, LAG using nitromethane as liquid and (caf)$(26diFBA) as seed, LAG using nitromethane as liquid and (caf)$(3FBA)
as seed, LAG using nitromethane as liquid and (caf)$(2345tetraFBA) as seed; blue: 1 obtained via LAG without the deliberate use of a seed in the (caf)$(FBA)
contaminated laboratory (utilising nitromethane as liquid)]; (e) Raman spectra of a caf : BA physical mixture before and after being exposed to a seed-contaminated
atmosphere [from bottom to top: b-caf (black), BA (black), physical mixtures of caf and BA sonicated for 5 min (red), physical mixtures of caf and BA sonicated for 5 min
and subsequently slurried for 19 hours (red), caf : BA physical mixture from a sealed screening vial that converted to 1 upon exposure to the seed-contaminated
atmosphere (green), 1 (black)].
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View Article Onlinenucleation process and the seeding mechanisms in the Cam-
bridge laboratories.
Seeding experiments were also performed at AbbVie Inc.
aer earlier attempts to prepare 1 without the use of hetero-
nuclear seeds failed. The initial “seedless” cocrystal screens
were based on the NG, LAG and SMPT techniques whereby
ethanol, acetonitrile and nitromethane were used as liquids/
solvents. Aer attempts to prepare the target cocrystal failed,
four cocrystals that were isomorphous with the lowest-energy
predicted target cocrystal (i.e. (caf)$(2FBA), (caf)$(23diFBA),
(caf)$(25diFBA) and (caf)$(26diFBA)) were used as heteronuclear
seeds, to successfully accomplish the synthesis of 1 (Fig. 4d).
The AbbVie group subsequently performed another series of
screening experiments, this time without the use of seeds in
order to determine the occurrence of possible laboratory
contamination and unintentional seeding, as seen in the
Cambridge laboratory. Indeed, a LAG experiment conrmed
that 1 could be now obtained without the deliberate use of4422 | Chem. Sci., 2013, 4, 4417–4425seeds. Another SMPT experiment was conducted using a phys-
ical mixture of caf and BA that was stored in a rubber-septa-
sealed vial before any heteronuclear cocrystal seeds were
introduced to the AbbVie laboratory. The seedless SMPT co-
crystal screen was initialized by injecting acetonitrile through
the rubber septum into the solid mixture. In situ Raman spec-
troscopy measurements showed the presence of a physical
mixture in the sealed vial even aer an appreciable amount of
time (i.e. 19 h). During the isolation of the physical mixture by
ultracentrifugation, however, it was observed that the physical
mixture converted almost immediately into 1 (as evident from a
visible change in the particle morphology, Raman spectroscopy
data (Fig. 4e) and PXRD data (Fig. S4†)), thus demonstrating
that seemingly minuscule amounts of contaminants of either 1
or a (caf)$(FBA) in the laboratory are capable of inducing a
phase transformation in extremely short periods of time. It is to
be further noted that additional seeding experiments involving
two cocrystal seeds that are not isomorphous with the targetThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinecocrystal, namely (caf)$(3FBA) and (caf)$(2345tetraFBA), have
also successfully led to the formation of the (caf)$(BA) cocrystal
(Fig. 4d). Interestingly, the (caf)$(BA) cocrystal was obtainable
without the use of seeds even aer more than one year aer the
initial seeding experiments were conducted.
Original eﬀorts to prepare 1 at the University of Zagreb also
failed. Both FBA and (caf)$(FBA) seeds were thus utilised to
facilitate nucleation and growth of the target cocrystal (see
Fig. S7, ESI†). The use of crystals of pure FBAs as seeds was
attempted to determine whether a heteronuclear seed could be
formed in situ through addition to a caf : BA physical mixture,
while the non-isomorphous (caf)$(FBA) cocrystals were selected
as seeds to explore the role of epitaxy in the formation of 1.67
Specically, 3FBA, 2345tetraFBA, (caf)$(2345tetraFBA) and
(caf)$(3FBA) were initially used to attempt the formation of the
target cocrystal, using LAG as the crystallization method. PXRD
studies showed that all four experiments yielded the target co-
crystal. These ndings indicate that: (a) that the cocrystal seed
and the cocrystal target do not have to be isomorphous, again
pointing to the possible role of epitaxy in the nucleation of 1,
and (b) that the heteronuclear seed could be generated in situ by
addition of the cocrystal former (i.e. FBAs) to the reaction vessel.
Crystallization experiments wherein 2FBA, (caf)$(2FBA),
23diFBA, (caf)$(23diFBA), 25diFBA, (caf)$(25diFBA), 26diFBA
and (caf)$(26diFBA) were utilized as seeds also resulted in the
formation of the target cocrystal, as expected. Notably, the
target cocrystal was obtainable without the use of seeds for up to
six weeks aer the earlier seeding experiments were performed;
thereaer, cocrystallization attempts involving caf and BA alone
began to fail again.
All results obtained by the Iowa group were consistent with
the ones gathered in Cambridge, Zagreb and at AbbVie – co-
crystal 1 could only be obtained aer the crystallization exper-
iments were aided by the use of (caf)$(FBA) seeds (see Fig. S8,
ESI†). Specically, (caf)$(2FBA) was found to facilitate the
quantitative formation of the target cocrystal in a SMPT exper-
iment using acetonitrile as solvent. While 2FBA, 23diFBA,
25diFBA and 26diFBA led to cocrystal formation during LAG
experiments performed by the Zagreb group, the same FBAs
were not found to seed cocrystal formation during SMPT-based
screens at Iowa. This was attributed to the inability of the FBA to
form (caf)$(FBA) seeds under the screening conditions owing to
the complete solubilisation of the FBA in the solvent.
Finally, given the remarkable sensitivity of the formation of 1
to the presence of miniscule amounts of contaminants in the
laboratory environment, it was unclear whether the testing
laboratories were suitable for the evaluation of the seeding
ability of any (caf)$(FBA) cocrystal seed. To determine whether
each of the studied (caf)$(FBA) cocrystals indeed acts as a seed
for the target cocrystal, the AbbVie group has preformed a series
of control experiments.
Physical mixtures of caf and BA (being stored in rubber-
septa-sealed vials before the initial heteronuclear cocrystal
seeds were conducted) were subjected to an SMPT cocrystal
screen by injecting a small amount of acetonitrile through the
rubber septum into the vial. In situ Raman spectroscopy
measurements showed that no cocrystal formation occurredThis journal is ª The Royal Society of Chemistry 2013even aer 112 h of slurrying. Suspensions containing small
amounts of one of the cocrystals that are isomorphous with 1,
namely (caf)$(2FBA), (caf)$(23diFBA), (caf)$(25diFBA), and
(caf)$(26diFBA), were then injected to the suspension of the
physical mixture. In situ Raman spectroscopy measurements
revealed that the physical mixture converted to the cocrystal
within a few minutes post-injection, thus proving that each of
the utilised (caf)$(FBA) cocrystals can seed the formation of the
target cocrystal. The outcomes of control experiments involving
the non-isomorphous (caf)$(3FBA) and (caf)$(2345tetraFBA)
were not conclusive and could not be used to determine
whether these cocrystals can or cannot seed the formation of
the target cocrystal.
To verify that FBA cocrystal formers can also be utilised to
facilitate the formation of 1, a suspension of 25diFBA crystals
was injected into the vial with the physical mixture of caf and
BA. The formation of 1 was observed only aer 45 minutes. The
longer period required to achieve the crystallisation of the target
compound is consistent with our hypothesis that the addition
of the FBA cocrystal former rst leads to the in situ formation of
the (caf)$(FBA) cocrystal seeds, which then facilitates the
formation of 1.Conclusion and outlook
That the cocrystal 1 failed to form, even though a stable co-
crystal form was predicted to exist, is possibly attributable to a
kinetic barrier that hinders the nucleation and growth of the
thermodynamically stable target cocrystal. The results pre-
sented herein illustrate that elusive multi-component crystal
forms can be obtained using cocrystals based on structurally
similar cocrystal formers. The results also demonstrate the
utility of crystal structure prediction calculations in assessing
the likelihood of cocrystal formation. In addition, the results
clearly demonstrate that current cocrystal-screening methods
need to be improved in order to eliminate the occurrence of
false negative results in cocrystal screens, which can seriously
impede the development of medicines and functional materials
(e.g. cocrystals and coordination compounds with relevant
electronic or catalytic properties). Further studies will focus on
elucidating the cause of the problematic nucleation of 1, as well
as on the development of a thorough understanding of the
presumed epitaxial growth of 1 on the surfaces of the
(caf)$(FBA) cocrystals.Acknowledgements
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